论文部分内容阅读
雌、孕激素主要来源于卵巢,已经证实乳腺癌及宫体癌有类固醇受体存在预示对激素治疗有效。近10年已有文献报道卵巢癌中存在类固醇受体,但对于受体的确切作用及临床价值了解甚少。本文的研究目的是将卵巢癌的受体浓度、芳香化酶活性及患者的生存期资料进行相关分析。进行雌激素受体(ER)、孕激素受体(PR)及雄激素受体(AR)测定的肿瘤组织取自怀疑卵巢恶性肿瘤而未进行筛选的105例病人。9例交界恶性肿瘤及14例由肠道、乳腺、输卵管转移而来的腺癌从研究中剔除,4例(6.0%)取自初次手术时卵巢癌的转移部位。肿瘤的组织学分类采用WHO标准。所有病人均进行了随访。随机选择39例肿瘤组织
Estrogen and progesterone are mainly derived from the ovary. The existence of steroid receptors in breast and uterine cancer has been shown to be effective in hormone therapy. Nearly 10 years have reported the presence of steroid receptors in ovarian cancer, but little is known about the exact role of the receptor and its clinical value. The purpose of this study was to correlate ovarian cancer receptor concentration, aromatase activity, and patient survival data. Tumor tissues from the estrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) were taken from 105 patients with suspected ovarian malignancy without screening. Nine cases of borderline malignant tumors and 14 cases of adenocarcinomas that metastasized from the gut, breast and fallopian tubes were excluded from the study. Four cases (6.0%) were taken from the metastatic site of ovarian cancer at initial surgery. Tumor histological classification using WHO standards. All patients were followed up. 39 cases of tumor tissue were randomly selected